This program is developing a potential inhaled therapy to deliver normal CFTR messenger RNA (mRNA) to the lungs. Lung cells would then use the instructions in the mRNA to create functional CFTR protein. This type of therapy could work for any person with CF, regardless of their CFTR mutations.

Status

Laboratory studies to develop and test this potential therapy are underway.

Sponsor

This program is sponsored by Arcturus Therapeutics and is partially funded by the Cystic Fibrosis Foundation.